Search

Displaying results 3981 - 3990 of 6835 in total
  1. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response. … XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia.

  2. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    by sulphate. … Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS) and

  3. Drug

    Bumadizone

    go.drugbank.com/drugs/DB13286
    Approved

    Its use is restricted to these conditions, due to risks this drug poses [L5650].

  4. Drug

    Oxyphenonium

    go.drugbank.com/drugs/DB00219
    Approved

    A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine. … It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]

  5. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets.

  6. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple … CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

  7. Drug

    Luteinizing hormone

    go.drugbank.com/drugs/DB14741
    ApprovedInvestigational

    Mixtures: MENOGON 75 IU LIYOFILIZE TOZ ICEREN AMPUL,5 ADET, MENOPUR 150 IU IM VE SC ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 5 ADET
  8. Drug

    Dihydroxymethoxychalcone

    go.drugbank.com/drugs/DB14122
    Investigational

    Cardamonin (also known as Dihydroxymethoxychalcone), as shown by the increasing number of publications, has received growing attention from the scientific community due to the expectations toward its benefits … to human health.

  9. Drug

    Tulathromycin A

    go.drugbank.com/drugs/DB11474
    ExperimentalVet approved

    Tulathromycin is a macrolide antibiotic used to treat bovine respiratory disease in cattle and swine respiratory disease in pigs. It is marketed by Pfizer Inc. under the tradename Draxxin.

  10. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.